Managing the risk of transfusion‐transmitted malaria from Australian blood donations: Recommendation of a new screening strategy

Abstract

AbstractBackground and ObjectivesTo reduce the risk of transfusion‐transmitted malaria (TTM) from transfusible components, Australia tests for malaria antibodies in both travellers returning from and former residents of malaria‐endemic areas. The testing is performed a minimum of 120 days after last potential exposure. TTM is an extremely rare event and managing the risk adds considerable complexity. The objectives of this study were to analyse various testing and deferral strategies, considering the risk, donation numbers and operational complexities.Materials and MethodsA residual risk model was developed to calculate the risk of TTM in five testing/deferral strategies. Australian blood donor data from 2020 and 2021 were used and incorporated the incidence of parasitaemia, Plasmodium species and the malaria enzyme immunoassay test's failure rate. Donor and donation loss or gain and an operational assessment were performed.ResultsThe current model's estimated risk of TTM is 1 in 67.9 million transfused units. Testing residents with a 120‐day plasma restriction for visitors without testing was found to have the same estimated risk, with an expected increase of 342 donations per year, significant cost savings and a 62% reduction in the number of donors requiring assessment.ConclusionA strategy that involves testing residents of malaria areas only and a 120‐day plasma travel restriction would not significantly increase the risk of TTM, is operationally simpler, costs less and results in a small increase in donations.